摘要
目的:探讨CXCL12-CXCR4趋化因子轴与卵巢癌的关系。方法:将转染质粒SKOV3/CXCR4、转染载体SKOV3/neg及未转染的SKOV33种卵巢癌细胞进行体外培养;将受试对象根据培养液的不同分为A、B、C、D4组,采用四甲基偶氮唑蓝(MTT)比色法进行增殖实验,判断CXCL12及CXCR4拮抗剂对卵巢癌细胞株的作用;测量不同的卵巢癌细胞株所获得的肿瘤情况。结果:①SKOV3/CXCR4组中A、B组细胞的增殖数高于C、D组及对照组(P<0.05),且B组高于A组(P<0.05);SKOV3/neg与SKOV3两组中A、B、C、D各组的细胞的增殖数差异无统计学意义(P>0.05)。②SKOV3/CXCR4处理组的裸鼠体重差值小于对照组,移植瘤的重量小于对照组,生存时间长于对照组,差异均有统计学意义(P<0.05)。③SKOV3/neg及SKOV3组的对照组与处理组比较差异无统计学意义(P>0.05)。结论:CXCL12-CXCR4趋化因子轴可促进卵巢癌细胞株的生长,是卵巢癌增值、转移的重要原因之一,而CXCR4拮抗剂可以抑制卵巢癌的生长。
Objective：To investigate the potential value of chemokine CXCL12-CXCR4 in the growth of o- varian cancer cells. Methods：SKOV3 cells transfected with CRCX4 vector or plasmid,as well as untransfect- ed SKOV3 cells,were cultured in vitro, and assigned into 4 groups （A, B, C, and D）cell proliferation was measured using MTT Assay. Results ：①In SKOV3/CXCR4 group,the cell proliferation in A and B groups is higher than that in C and D groups（ P 〈0.05） ;And the cell proliferation in B group is higher than A group （P〈0. 05） ;②In SKOV3/CXCR4 group,the number and weight of metastatic tumors in experimental group are lower than those in control group. The live time of nude mice is longer than that in control group （ P 〈 0.05） ;③In SKOV3/neg and SKOV3 group, no significantly differences of the experimental data are ob- served. Conclusiona：Chemokine CXCL12-CXCR4 mightimprove the growth of ovarian cancer cells. The CX- CR4 antibody and antagonist AMD3100 might inhibit the growth of ovarian cancer cells.
出处
《实用妇产科杂志》
CAS
CSCD
北大核心
2013年第1期49-52,共4页
Journal of Practical Obstetrics and Gynecology
关键词
卵巢癌
CXCL12
CXCR4
CXCR4拮抗剂
细胞增值
Ovarian cancer
Stromoal cell-de-rived factor-12
C-X-C chemokine receptor4
C-X-C chemo-kine receptor4 antagonists
Cell proliferation
